ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Safety"

  • 2018 American Transplant Congress

    Alemtuzumab Induction is Effective and Safe in Elderly Kidney Transplant Recipients

    A. Toledo, K. Szempruch, P. Serrano, K. Andreoni, T. Kozlowski.

    University of North Carolina, Chapel Hill.

    Purpose of this study is to determine safety of Alemtuzumab (Ab) in elderly kidney recipients.MethodsThis is a retrospective single center cohort analysis concerning kidney transplant…
  • 2018 American Transplant Congress

    Water-Jet Dissection for Donor Hepatectomy during Living Donor Liver Transplantation

    K. Gotoh,1 H. Eguchi,1 Y. Iwagami,1 D. Yamada,1 T. Asaoka,1 T. Noda,1 K. Kawamoto,1 S. Kobayashi,1 K. Umeshita,2 Y. Doki,1 M. Mori.1

    1Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; 2Health Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

    Background The most important issue in living donor liver transplantation (LDLT) is donor safety. Although donor hepatectomy has evolved technically over the years, it is…
  • 2018 American Transplant Congress

    Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus

    N. Undre,1 J. Rubik,2 D. Debray,3 D. Kelly,4 F. Iserin,5 N. Webb,6 P. Czubkowski,2 K. Vondrak,7 A-.L. Sellier-Leclerc,8 S. Riva,9 B. Tönshoff,10 L. D'Antiga,11 S. Marks,12 R. Reding,13 G. Kazeem.1

    1Astellas Pharma Europe Ltd, Chertsey, United Kingdom; 2Children's Memorial Health Institute, Warsaw, Poland; 3APHP-Hôpital Universitaire Necker, Paris, France; 4Birmingham Children's Hospital, Birmingham, United Kingdom; 5University Hospital Necker Enfants Malades, Paris, France; 6Manchester University Foundation Trust, Manchester, United Kingdom; 7University Hospital Motol, Prague, Czech Republic; 8Hôpital Femme-Mère-Enfant, Bron Cedex, France; 9ISMETT-IRCCSS, Palermo, Italy; 10University Children's Hospital, Heidelberg, Germany; 11Hospital Papa Giovanni XXIII, Bergamo, Italy; 12Great Ormond Street Hospital for Children, London, United Kingdom; 13Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium.

    Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…
  • 2018 American Transplant Congress

    Laparoscopic Donor Nephrectomy Safety: Experience of 500 Cases in Hispanic Population at a Single Institution

    Y. Baez Suarez, F. Giron Luque, J. Amaya Nieto.

    Transplantation Surgery, Colombiana de Trasplantes, Bogota, Colombia.

    Background: Laparoscopic live donor nephrectomy (LDN) has become the best option in living donation because its safety and low rate of complications. This report aims…
  • 2018 American Transplant Congress

    Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study

    S. Mulgaonkar,1 Y. Qazi,1 D. Kim,1 V. Peddi,1 K. McCague,2 D. Patel,2 A. Wiseman.1

    1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.

    Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…
  • 2018 American Transplant Congress

    Immunoglobulin Replacement Therapy in Pediatric Renal Transplant Patients

    A. Lewis, M. Fasano, D. Zepeda-Orozco.

    University of Iowa Hospitals and Clinics, Iowa City, IA.

    Immunoglobulin replacement therapy decreases infection frequency in patients with primary immunodeficiency; however, there is limited data regarding the use of intravenous immunoglobulin (IVIG) or subcutaneous…
  • 2018 American Transplant Congress

    Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies

    F. Shihab,1 Y. Qazi,1,2 V. Peddi,1 D. Shaffer,1 D. Kim,1,2 K. McCague,3 D. Patel,3 S. Mulgaonkar.1,2

    1US92 Study Group, Salt Lake City; 2TRANSFORM Study Group, East Hanover; 3Novartis Pharmaceuticals Corporation, East Hanover.

    Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…
  • 2018 American Transplant Congress

    Pediatric Kidney Transplant in Norway – Results after Switching from Midline to Retroperitoneal Approach in Recipients below 25 kg

    R. Horneland, A. Khan, G. Steinar, T. Thorsen, M. Hagness.

    Section for Transplant Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

    Introduction: Pediatric kidney transplants demand a high level of surgical and medical involvement and skill. In Norway, all organ transplants are centralized and performed at…
  • 2018 American Transplant Congress

    mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial

    L. Jeng,1 S. Lee,1 A. Soin,1 S. Uemoto,1 D. Maluf,1 J. Emond,1 M. Meier,2 J. Kochuparampil,2 C. Sips,2 S. Kaneko,3 G. Levy.1

    1H2307 Study Group, Taichung, Taiwan; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharma KK, Tokyo, Japan.

    Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…
  • 2018 American Transplant Congress

    Radiation Exposure to the Transplant Surgeon: A Case Study of Recent Yttrium-90 Treatment in an Explanted Liver

    M. Decoteau,1 P. Lewis,1 S. Steuterman,2 R. Schaffer,1 J. Fisher,1 J. Case,1 C. Marsh.1

    1Organ Transplantation, Scripps Green Hospital, La Jolla, CA; 2Medical Physics & Radiation Safety, Scripps Green Hospital, La Jolla, CA.

    BACKGROUND: Yttrium-90 (Y-90) radioembolization for the treatment of hepatocellular carcinoma can present safety challenges to the surgeon when transplanting a recently treated Y-90 patient. To…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 19
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences